Project description:Human colorectal cancer organoids were treated with the TROP2-targeting antibody-drug conjugate Sacituzumab Govitecan (SG) or non-targeting control IgG1-SN-38. Samples were harvested at different time points under treatment {0h, 3h, 6h, 9h, 12h} as well as after drug washout at 12 h on the following time points {12h + 12h, 12h + 36h, 12h + 60h}. Samples were subjected to single-cell RNA-seq using sample hashtag multiplexing.
Project description:Patient-derived colorectal cancer organoids were injected into mice to grow into subcutaneous tumors. Starting at 100 mm3, tumors were treated with Trodelvy (Sacituzumab Govitecan (SG)) or vehicle twice per week for 28 days before samples were harvested and subjected to single-cell RNA-sequencing of the tumor cells.
Project description:Patient-derived colorectal cancer organoids were injected into mice to grow into subcutaneous tumors. Tumors were profiled through multiplexed single-cell RNA-sequencing.
Project description:Primary tumor or liver metastasis biopsies were obtained from colorectal cancer patients and processed for multiplexed single-cell RNA-sequencing.